drugset / Trial / NCT01427972

A Study of LY2623091 in Male and Females With Chronic Kidney Disease

NCT01427972

Phase 2 Completed 42 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this trial is to investigate the safety and efficacy of LY2623091 in males and females with chronic kidney disease.

Timeline

Start
2011-09
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eplerenone Unknown 50 mg Oral
Subject LY2623091 Small molecule 0.2 mg Oral
Subject LY2623091 Small molecule 1.5 mg Oral
Subject LY2623091 Small molecule 10 mg Oral